Shijiazhuang Yiling Pharmaceutical Co.

Shijiazhuang, China

Shijiazhuang Yiling Pharmaceutical Co.

Shijiazhuang, China
SEARCH FILTERS
Time filter
Source Type

Patent
Shijiazhuang Yiling Pharmaceutical Co. | Date: 2012-09-26

()-(S)-3-(3-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.


The present invention relates to a pyrrole-substituted indolone derivative, a preparation method therefor, a composition comprising the derivative, and use thereof. The pyrrole-substituted indolone derivative has a structure shown in formula (I) below. The present invention further relates to use of the pyrrole-substituted indolone derivative for treating receptor tyrosine kinase-mediated diseases, and to a pharmaceutical composition comprising compounds having such a structure for treating related diseases such as tumors.


The present invention relates to a pyrrole-substituted indolone derivative, a preparation method therefor, a composition comprising the derivative, and use thereof. The pyrrole-substituted indolone derivative has a structure shown in formula (I) below. The present invention further relates to use of the pyrrole-substituted indolone derivative for treating receptor tyrosine kinase-mediated diseases, and to a pharmaceutical composition comprising compounds having such a structure for treating related diseases such as tumors.


Patent
Shijiazhuang Yiling Pharmaceutical Co. | Date: 2016-02-12

()-(S)-3-(3-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.


Patent
Shijiazhuang Yiling Pharmaceutical Co. | Date: 2014-08-20

(-)-(S)-3-(3-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.


Liu M.,Peking University | Liu M.,Shijiazhuang Yiling Pharmaceutical Co. | Zhao S.,Shijiazhuang Yiling Pharmaceutical Co. | Wang Z.,Shijiazhuang Yiling Pharmaceutical Co. | And 6 more authors.
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences | Year: 2014

Deoxyschizandrin is an active lignin ingredient originating from Schisandra chinensis (Turcz.) Baill or Schisandrae Sphenantherae Fructus. In the present study, a novel and efficient strategy was developed for the in vivo screening and identification of deoxyschizandrin metabolites using ultra high performance liquid chromatography combined with triple TOF mass spectrometry (UPLC-TOF/MS/MS). This strategy was characterized by the following: a novel and unique multiple mass defect filter (MMDF) combined with an on-line data acquisition method that is dependent on dynamic background subtraction (DBS) was developed to trace all of the probable metabolites of deoxyschizandrin. The MMDF and DBS methods could trigger an IDA scan for the low-level metabolites that are masked by background noise and endogenous components. A combination of data processing methods including extracted ion chromatography (XIC), mass defect filtering (MDF), product ion filtering (PIF) and neutral loss filtering (NLF) were employed to identify the metabolites of deoxyschizandrin. Next, the structures of the metabolites were elucidated based on an accurate mass measurement, the fragmentation patterns of the parent drug and relevant drug bio-transformation knowledge. Finally, an important parameter Clog. P was used to estimate the retention time of isomers. Based on the proposed strategy, 51 metabolites (including 49 phase I and 2 phase II metabolites) were identified in rats after the oral administration of deoxyschizandrin. Among these metabolites, 41 metabolites were characterized in the rat urine, and 28 metabolites were identified in the rat bile. The results indicated that oxidization was the main metabolic pathway and that the methoxy group and the biphenyl cyclooctene were the metabolic sites. Conjugation with sulfate and cysteine groups produced two phase-II metabolites. This study firstly reported the description of deoxyschizandrin metabolism in vivo. This study provided a practical strategy for rapidly screening and identifying metabolites, and this methodology can be widely applied for the structural characterization of the metabolites of other compounds. © 2013 Elsevier B.V.


Liu M.Y.,Shijiazhuang Yiling Pharmaceutical Co.
Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials | Year: 2013

To establish an HPLC method for simultaneous determination of six organic acids in Lonicerae japonicae Flos and Lonicerae Flos in different habitats. The chromatographic separation was carried out on a Waters C18 column (4. 6 mm x 250 mm, 5 microm) with gradient elution of acetonitrile and 0.1% phosphoric acid at a flow rate of 1 mL/min. The detection wave-length was 326 nm. The contents of neochlorogenic acid and cryptochlorogenic acid in Lonicerae japonicae Flos in different habitats were very low. The contents of chlorogenic acid in Lonicerae japonicae Flos in Pingyi, Fei County, Fengqiu and Jvlu were significantly higher than that in Shangluo, but the contents of other organic acids were similar. The contents of six kinds of organic acids in Lonicerae Flos in different origins were obviously higher than those in Lonicerae japonicae Flos. A simple, accurate and credible method is developed and validated for quality control of six organic acids from Lonicerae japonicae Flos and Lonicerae Flos.


PubMed | Shijiazhuang Yiling Pharmaceutical Co. and Hebei Medical University
Type: Journal Article | Journal: Journal of chromatographic science | Year: 2016

The aim of this study was to investigate the chemical differences between genunine Isodon japonica and its adulterants. A linear ion trap liquid chromatography with tandem mass spectrometry analytical method has been developed for the identification and quantification of 14 major diterpenoids in I. japonica. Data acquisition was multiple reaction monitoring transitions mode followed by an information-dependent acquisition using the enhanced product ion (EPI) scan in a single run. The target compounds were further identified and confirmed using an EPI spectral library. Overall validation of the assay was carried out including linearity, accuracy, precision, limits of detection and quantification. The results demonstrated that the method was selective, sensitive and reliable. The determination results of 21 batches of I. japonica and adulterants were then analyzed and differentiated by hierarchical clustering analysis.


Trademark
Shijiazhuang Yiling Pharmaceutical Inc. | Date: 2013-10-30

nutritional food additives for medical purposes in the nature of natural food extracts derived from fish, meat, vegetables and fruits; dietary and nutritional supplements; dietary supplemental drinks in the nature of vitamin and mineral beverages; nutritionally fortified beverages; nutritional supplements; mineral food supplements; vitamin preparations; health food supplements; medicines for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medicinal drinks; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical products for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; antibiotics; medicinal herbs. non-alcoholic fruit extracts used in the preparation of beverages; non-alcoholic fruit juice beverages; fruit juices; non-alcoholic beverages, namely, carbonated beverages, non-alcoholic beer, non-alcoholic cocktails, energy shots, non-alcoholic malt beverage and non-alcoholic honey-based beverages; fruit nectars; sherbets beverages; aerated water; water beverages; mineral water; concentrates, syrups or powders used in the preparation of soft drinks, sports drink, energy drinks and fruit drinks; fruit beverages; essences for making non-alcoholic beverages, mineral waters and soft drinks, not in the nature of essential oils; lemonades; table waters; smoothies.


Trademark
Shijiazhuang Yiling; Pharmaceutical Co. | Date: 2010-04-06

Pharmaceutical preparations for the treatment of cardiovascular system diseases, namely, hypertension, and heart failure; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of nutrition metabolism barrier diseases, namely, malnutrition and beriberi; Pharmaceutical preparations for the treatment of metabolism diseases, namely, diabetes, obesity, diabetic ketoacidosis, hypoxemia DKA and high fat proteinemia; Pharmaceutical preparations for the treatment of endocrine system diseases, namely, next cerebral ganglion pituitary gland sickness, thyroid gland sickness, ophoropathy and parathyroid sickness; Pharmaceutical preparations for the treatment of circulatory system diseases, namely, shock, heart valve sickness, arrhythmia, arteriosclerosis, cardiomyopathy periphery blood vessel disease, hypertensive disease and pericarditis; Pharmaceutical preparations for the treatment of respiratory disorder, namely, chronic bronchitis, bronchial asthma, disease of pulmonary circulation, pneumonia and acute trachea bronchitis; Pharmaceutical preparations for the treatment of digesting system diseases, namely, abdominal pain, constipation, diarrhea, cholecystitus, liver cirrhosis, liver function failure and gastritis; Pharmaceutical preparations for the treatment of urinary system diseases, namely, kidney stone, renal tumor, chronic kidney function failure, urinary tract infection and cystonephrosis; Pharmaceutical preparations for the treatment of hematopoietic system diseases, namely, anemia, leukemia and lymphoma; Pharmaceutical preparations for the treatment of immune system diseases, namely, serum sickness, allergic shock and allergic rhinitis; Pharmaceutical preparations for the treatment of rheumatic diseases and osteoarthritis, namely, rheumatic fever, lupus erythematosus, sjogrens syndrome, behcet disease and dermatomyositis; Pharmaceutical preparations for the treatment of nerve diseases, namely, schizophrenia and neurosis; Pharmaceutical preparations for the treatment of nervous system diseases, namely, headache, multiple sclerosis and muscle diseases; Pharmaceutical preparations for the treatment of skin diseases, namely, eczema, belt-shaped blister measles, namely, herpes zoster, connective tissue disease, lupus erythematosus and nervous dermatitis; Pharmaceutical preparations for the treatment of reproductive system inflammation, namely, pelvic inflammatory disease, cervicitis and vestibule big gland inflammation; Pharmaceutical preparations for the treatment of natural dissemination diseases, namely, gonorrhea, syphilis and AIDS; Pharmaceutical preparations for the treatment of female reproductive system tumor, namely, sarcoma uteri, carcinoma of cervix and endometrium cancer; Pharmaceutical preparations for the treatment of menopathy, namely, menopause, painful menstruation and menopause syndrome; Pharmaceutical preparations for the treatment of newborn symptom and diseases, namely, the newborn faints from fright, newborn vomit and newborn septicaemia; Pharmaceutical preparations for the treatment of surgical department conditions, namely, tetanus, wounds and tumors.

Loading Shijiazhuang Yiling Pharmaceutical Co. collaborators
Loading Shijiazhuang Yiling Pharmaceutical Co. collaborators